A Successful Transition from Europe to the US Market

The Challenge

The Challenge

To ensure broad access for their supportive care technology, a European-based medical device company looking to enter the US market sought guidance and support in understanding the US payer system and how to gain buy-in from US healthcare providers.

The IP Solution

The IP Solution

To help this European-based company navigate the complexities of the US Healthcare Landscape, our first step was to engage thought leaders across major academic cancer centers and community oncology networks to gain support for the product.

The next step was to achieve inclusion for the product within the clinical compendia as a supportive care treatment across multiple tumor types. We engaged in a series of meetings with thought leaders to garner insight, and then— with support from our team of expert medical writers—provided critical guidance to the company’s internal team in writing and submitting formal requests to major oncology clinical compendia organizations.

[IP has] a huge amount of experience and connections in the industry but what I love about them is that they are honest, supportive and ultimately want us to succeed.

CEO, Medical Device Company
The Result

The Results

The strategy proved successful, and the device was recognized within the clinical guidelines and compendia, ensuring access for providers and payers.

Related Case Studies

Healthcare policy changes interpreted in real-time

A European-based pharmaceutical company with several products in the US market was under pressure to interpret and respond to rapidly changing US healthcare policies which could potentially impact access for their portfolio of oncology products.

A comprehensive launch strategy leads to broad access

A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.

Understanding the European Market

A mid-sized pharmaceutical company was looking to enter the European market through a compassionate use/early access pathway but lacked an understanding of the requirements specific to each country that would lead to broad access and reimbursement for their product across Europe.